Pfizer (NYSE:PFE) Trading Up 1.3% Following Earnings Beat

Shares of Pfizer Inc. (NYSE:PFE) shot up 1.3% during mid-day trading on Tuesday following a stronger than expected earnings report. The company traded as high as $25.64 and last traded at $25.3540. 59,974,558 shares changed hands during trading, an increase of 41% from the average daily volume of 42,391,031 shares. The stock had previously closed at $25.03.

The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the company posted $0.78 EPS. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer’s payout ratio is presently 131.30%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q2 results exceeded expectations: Pfizer reported adjusted earnings of $0.77 per share versus the $0.68 analyst consensus, while revenue reached $15.03 billion, ahead of the $14.40 billion estimate and up 2.6% year over year. Pfizer tops quarterly estimates, hikes low end of revenue guidance
• Positive Sentiment: Revenue guidance improved: Pfizer raised the low end of its 2026 revenue forecast from $59.5 billion to $60.5 billion, maintaining the $62.5 billion high end and lifting the midpoint by $500 million. Adjusted EPS guidance remains $2.80–$3.00, broadly consistent with expectations. Pfizer Reports Second-Quarter Results
• Positive Sentiment: Portfolio diversification is gaining traction: Strong demand for Eliquis, oncology medicines and recently acquired products helped drive the quarter, supporting management’s recovery strategy beyond legacy COVID products. Pfizer also plans an additional $2.5 billion in cost reductions through 2029. Pfizer beats quarterly profit estimates
• Positive Sentiment: Obesity-drug pipeline offers a longer-term catalyst: Pfizer said its monthly GLP-1 candidate could potentially rival tirzepatide on weight loss, although clinical data and regulatory milestones remain ahead. Pfizer Says Monthly GLP-1 Candidate Could Rival Tirzepatide
• Neutral Sentiment: Pfizer’s reported results included a quarterly loss, reflecting charges, while the adjusted figures investors typically follow showed an earnings beat. The company also reaffirmed EPS guidance after accounting for an approximately $0.10 impact from its Innovent Biologics transaction.
• Negative Sentiment: COVID-product revenue remains a major headwind: Pfizer reduced its COVID revenue forecast as demand for related vaccines and treatments continued to fall. This decline, along with concerns about the pace of the post-2028 growth recovery, limited the market’s reaction to the earnings beat. PFE Q2 Earnings Top, COVID Forecast Cut

Wall Street Analyst Weigh In

PFE has been the subject of a number of research reports. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Monday, July 6th. Wolfe Research reissued an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Finally, Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $28.50.

Institutional Investors Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Journey Advisory Group LLC raised its stake in shares of Pfizer by 8.8% in the 2nd quarter. Journey Advisory Group LLC now owns 34,607 shares of the biopharmaceutical company’s stock valued at $833,000 after purchasing an additional 2,809 shares during the period. Strive Financial Group LLC increased its stake in shares of Pfizer by 29.9% during the 2nd quarter. Strive Financial Group LLC now owns 9,474 shares of the biopharmaceutical company’s stock worth $228,000 after purchasing an additional 2,181 shares during the last quarter. Leuthold Group LLC acquired a new stake in Pfizer during the 2nd quarter valued at $4,887,000. BCGM Wealth Management LLC boosted its holdings in shares of Pfizer by 4.8% during the 2nd quarter. BCGM Wealth Management LLC now owns 57,029 shares of the biopharmaceutical company’s stock worth $1,373,000 after buying an additional 2,631 shares during the period. Finally, Virtus Family Office LLC grew its stake in Pfizer by 9.6% in the 2nd quarter. Virtus Family Office LLC now owns 70,574 shares of the biopharmaceutical company’s stock valued at $1,699,000 after buying an additional 6,173 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

The stock has a market capitalization of $144.50 billion, a P/E ratio of 19.35 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company’s fifty day simple moving average is $25.03 and its two-hundred day simple moving average is $26.16.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.